Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Epix Expanded Agreement With Cystic Fibrosis Foundation Valued At $50 Million

This article was originally published in The Pink Sheet Daily

Executive Summary

Extended deal includes potential for $37.7 million in payments to Epix, which is developing 3-D model of key protein associated with CF.

You may also be interested in...



Epix Finally Sells Vasovist and Flips Debt, But Will It Escape Bankruptcy?

Marrying off drugs inherited in Predix merger could help firm stay afloat.

Epix Finally Sells Vasovist and Flips Debt, But Will It Escape Bankruptcy?

Marrying off drugs inherited in Predix merger could help firm stay afloat.

Vertex Advance In Cystic Fibrosis May Treat The Underlying Disease

10 percent increase in lung function seen in Phase IIa could mean five to 10 years for some CF patients if outcome is sustained in further trials.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS067700

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel